Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Material Agreement (Mar 4, 2024)

Reports
Material Agreements
Filing Date
Filed March 4, 2024
Period End
March 1, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · May ’23May ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed March 4, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (the "Company") reported in this Form 8-K filed March 4, 2024 that certain of its subsidiaries, including Eidos Therapeutics, Inc. ("Eidos"), BridgeBio International GmbH and BridgeBio Europe B.V., entered into an exclusive license agreement on March 1, 2024 with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG ("Bayer").

The agreement covers developing and commercializing acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the "Licensed Territory"). Under the agreement, Eidos grants Bayer an exclusive license to certain intellectual property rights for acoramidis (AG10) in the Licensed Territory, effective upon receipt of certain antitrust clearances. In consideration, Eidos is entitled to receive up to $310 milliona in upfront, regulatory and sales milestone payments through 2026, plus additional payments tied to certain sales milestones.

Eidos is also entitled to tiered royalties starting in the low-thirties percent on Bayer's net sales of acoramidis in the Licensed Territory, subject to reduction in certain circumstances. The agreement runs until the end of the royalty term for a licensed product, unless terminated earlier. Either party may terminate for material breach or insolvency of the other, or if merger control proceedings start and clearances are not obtained.

Bayer may terminate for convenience on at least 270 days' prior written notice, and Eidos may terminate if Bayer ceases exploitation of acoramidis under certain circumstances or challenges Eidos' patent rights. The full agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ending March 31, 2024.

Key Highlights

  1. Agreement dated March 1, 2024 grants Bayer Consumer Care AG an exclusive license to develop and commercialize acoramidis for transthyretin amyloidosis in the EU and European Patent Organization member states.
  2. Eidos is entitled to up to $310 million in upfront, regulatory and sales milestone payments through 2026, plus additional sales-milestone-based payments.
  3. Eidos will receive tiered royalties starting in the low-thirties percent on Bayer's net sales in the Licensed Territory, subject to certain reductions.
  4. The license becomes effective only after certain antitrust clearances are obtained.
  5. Bayer may terminate for convenience on at least 270 days' prior written notice; either party may terminate for material breach, insolvency, or failed merger control clearances.
  6. The full agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ending March 31, 2024.

Frequently Asked Questions

  1. What rights did BridgeBio grant to Bayer?

    Eidos granted Bayer an exclusive license to certain intellectual property rights to develop, manufacture and commercialize acoramidis (AG10) as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization.

  2. What payments can BridgeBio's subsidiary receive under the agreement?

    Eidos is entitled to receive up to $310 million in upfront, regulatory and sales milestone payments through 2026, and is eligible for additional payments tied to certain sales milestones. It is also entitled to royalties on Bayer's net sales of acoramidis in the Licensed Territory, starting in the low-thirties percent under a tiered structure.

  3. When does the license become effective?

    The exclusive license is effective upon the date that certain antitrust clearances have been obtained.

  4. How long does the agreement last and how can it be terminated?

    The agreement expires at the end of the royalty term for a licensed product, unless earlier terminated. Either party may terminate for material breach or insolvency of the other, or if merger control proceedings start and clearances are not obtained. Bayer may terminate for convenience on at least 270 days' prior written notice, and Eidos may terminate if Bayer ceases exploitation of acoramidis under certain circumstances or challenges Eidos' patent rights.

  5. Where can investors find the full terms of the agreement?

    The filing states that a copy of the full agreement will be filed with the SEC as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.